



Appl. S.N. 09/939,754
Atty. Docket No. 0125-0016D3

Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

McTigue et al.

Art Unit: 1631

Serial No. 09/939,754

Examiner: To Be Assigned

Filed: August 28, 2001

RECEIVED

For: Modifications of the VEGF Receptor-2
Protein and Methods of Use

JUL 12 2002

TECH CENTER 1600/2900

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Honorable Commissioner of Patents
And Trademarks
Washington, DC 20231

Sir:

Applicant(s) hereby request(s) that a corrected Official Filing Receipt be issued and sent to the undersigned representative.

Specifically, it is noted that the following are incorrect on the present Official Filing Receipt:

1. Under Assignment for Published Patent Application, the word Pharmaceuticals is misspelled, as Agouron Pharamceuticals, Inc. and should read Agouron Pharmaceuticals, Inc.

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red.

It is therefore respectfully requested that a corrected Official Filing Receipt be issued and officially entered into the case, which reflects the correction of all the above-noted error(s). It is further requested that the corrected Official Filing Receipt be sent to the undersigned at the earliest possible time.

Respectfully submitted,

SHANKS & HERBERT


By: 

Shelly Guest Cermak
Reg. No. 39,571

Date: 7/1/02

TransPotomac Plaza
1033 N. Fairfax Street
Suite 306
Alexandria, VA 22314

090PTO



UNITED STATES PATENT AND TRADEMARK OFFICE

Page 1 of 2

SGC/CG

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/939,754	08/28/2001	1631	710	0125-0016D3	67	10	1

CONFIRMATION NO. 3837

CORRECTED FILING RECEIPT



OC00000007231404

SHANKS & HERBERT
TransPotomac Plaza
Suite 306
1033 N. Fairfax St.
Alexandria, VA 22314

ec

Date Mailed: 12/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Michele A. McTigue, Encinitas, CA;
Chris Pinko, San Diego, CA;
Camran V. Parast, San Diego, CA;
Michael R. Gehring, Ramona, CA;
Chen-Chen Kan, Del Mare, CA;
Krzysztof Appelt, Poway, CA;
John A. Wickersham, Escondido, CA;
Richard E. Showalter, Santee, CA;
Anna M. Tempczyk-Russell, San Diego, CA;
Barbara Mroczkowski, Encinitas, CA;
Jesus E. Villafranca, San Diego, CA;

RECEIVED

JUL 12 2002

TECH CENTER 1600/2900

Assignment For Published Patent Application

Agouron Pharmaceuticals, Inc.;
Pharmaceuticals

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/390,326 09/07/1999 PAT 6,316,603
WHICH CLAIMS BENEFIT OF 60/099,503 09/08/1998

Foreign Applications

If Required, Foreign Filing License Granted 09/11/2001

Projected Publication Date: 03/14/2002

Non-Publication Request: No

Early Publication Request: No

Title

Modifications of the VEGF receptor-2 protein and methods of use

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).